The Coretec Group Inc. (CRTG) 10-Q 3 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 03, 2021
Document Information [Line Items]
Entity Central Index Key	0001375195
Entity Registrant Name	CORETEC GROUP INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	000-54697
Entity Incorporation, State or Country Code	OK
Entity Tax Identification Number	73-1479206
Entity Address, Address Line One	600 S. Wagner
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48103
City Area Code	866
Local Phone Number	916-0833
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		253,363,500

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 4,357,144	$ 22,219
Prepaid expenses	127,600	179,963
Total current assets	4,484,744	202,182
Other assets:
Intangibles, net	1,010,261	1,059,026
Goodwill	166,000	166,000
Deposits-other	7,196	18,946
Total other assets	1,183,457	1,243,972
Total Assets	5,668,201	1,446,154
Current liabilities:
Notes payable	0	46,580
Accounts payable and accrued expenses	311,224	396,019
Current portion of long term debt	407,930	0
Total current liabilities	719,154	442,599
Long term debt, net	793,104	266,598
Total Liabilities	1,512,258	709,197
Stockholders' equity:
Preferred stock, Series A convertible, $0.0002 par value, 500,000 shares authorized; 345,000 shares issued and outstanding at September 30, 2021 and December 31, 2020	69	69
Common stock $0.0002 par value, 1,500,000,000 shares authorized; 252,285,754 and 213,751,145 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.	50,456	42,750
Additional paid-in capital	17,216,935	8,033,313
Accumulated deficit	(13,111,517)	(7,339,175)
Total Stockholders' Equity	4,155,943	736,957
Total Liabilities and Stockholders' Equity	$ 5,668,201	$ 1,446,154

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	345,000	345,000
Preferred stock, shares outstanding (in shares)	345,000	345,000
Common stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Common stock, shares authorized (in shares)	1,500,000,000	1,500,000,000
Common stock, shares issued (in shares)	252,285,754	213,751,145
Common stock, shares outstanding (in shares)	252,285,754	213,751,145

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income:
Revenue	$ 0	$ 0	$ 0	$ 0
Expenses:
Research and development	192,255	37,197	428,251	117,187
General and administrative	2,480,697	316,376	5,340,325	780,491
Interest	44,077	80,531	175,015	357,615
Total expenses	2,717,029	434,104	5,943,591	1,255,293
Other income	45,124	0	45,124	1,250
Net loss	$ (2,671,905)	$ (434,104)	$ (5,898,467)	$ (1,254,043)
Loss per share:
Basic and diluted (in dollars per share)	$ (0.011)	$ (0.002)	$ (0.024)	$ (0.006)
Weighted average shares outstanding, basic and diluted (in shares)	251,965,750	203,710,642	240,775,933	200,016,816

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019						345,000	193,521,506
Balance at Dec. 31, 2019						$ 69	$ 38,704	$ 6,135,885	$ (5,494,193)	$ 680,465
Debt converted to common stock (in shares)						0	9,129,136
Notes payable converted to common stock						$ 0	$ 1,826	298,174	0	300,000
Warrants issued						0	0	53,447	0	53,447
Net loss for the period						0	0	0	(530,307)	(530,307)
Beneficial conversion feature of note payable						0	0	310,303	0	310,303
Net loss						$ 0	$ 0	0	(530,307)	(530,307)
Balance (in shares) at Mar. 31, 2020						345,000	202,650,642
Balance at Mar. 31, 2020						$ 69	$ 40,530	6,797,809	(6,024,500)	813,908
Balance (in shares) at Dec. 31, 2019						345,000	193,521,506
Balance at Dec. 31, 2019						$ 69	$ 38,704	6,135,885	(5,494,193)	680,465
Notes payable converted to common stock										300,000
Net loss for the period										(1,254,043)
Net loss										(1,254,043)
Balance (in shares) at Sep. 30, 2020						345,000	204,450,642
Balance at Sep. 30, 2020						$ 69	$ 40,890	7,353,503	(6,748,236)	646,226
Balance (in shares) at Mar. 31, 2020						345,000	202,650,642
Balance at Mar. 31, 2020						$ 69	$ 40,530	6,797,809	(6,024,500)	813,908
Exchange of stock options for common stock (in shares)						0	900,000
Exchange of stock options for common stock						$ 0	$ 180	(180)	0	0
Warrants issued						0	0	23,692	0	23,692
Net loss for the period						0	0	0	(289,632)	(289,632)
Beneficial conversion feature of note payable						0	0	191,839	0	191,839
Net loss						$ 0	$ 0	0	(289,632)	(289,632)
Balance (in shares) at Jun. 30, 2020						345,000	203,550,642
Balance at Jun. 30, 2020						$ 69	$ 40,710	7,013,160	(6,314,132)	739,807
Exchange of stock options for common stock (in shares)						0	900,000
Exchange of stock options for common stock						$ 0	$ 180	(180)	0	0
Warrants issued						0	0	31,454	0	31,454
Options issued for compensation and services						0	0	73,773	0	73,773
Net loss for the period						0	0	0	(434,104)	(434,104)
Beneficial conversion feature of note payable						0	0	235,296	0	235,296
Net loss						$ 0	$ 0	0	(434,104)	(434,104)
Balance (in shares) at Sep. 30, 2020						345,000	204,450,642
Balance at Sep. 30, 2020						$ 69	$ 40,890	7,353,503	(6,748,236)	646,226
Balance (in shares) at Dec. 31, 2020						345,000	213,751,145
Balance at Dec. 31, 2020	$ 0	$ 0	$ (988,900)	$ 126,125	$ (862,775)	$ 69	$ 42,750	8,033,313	(7,339,175)	736,957
Debt converted to common stock (in shares)						0	1,519,757
Notes payable converted to common stock						$ 0	$ 304	49,696	0	50,000
Common stock issued for liabilities (in shares)						0	1,716,447
Common stock issued for liabilities						$ 0	$ 343	69,921	0	70,264
Exchange of stock options for common stock (in shares)						0	1,200,000
Exchange of stock options for common stock						$ 0	$ 240	(240)	0	0
Private placement stock issuance (in shares)						0	23,500,000
Private placement stock issuance						$ 0	$ 4,700	4,908,500	0	4,913,200
Warrants issued						0	0	62,785	0	62,785
Options issued for compensation and services						0	0	18,723	0	18,723
Net loss for the period						0	0	0	(438,422)	(438,422)
Net loss						$ 0	$ 0	0	(438,422)	(438,422)
Balance (in shares) at Mar. 31, 2021						345,000	241,687,349
Balance at Mar. 31, 2021						$ 69	$ 48,337	12,153,798	(7,651,472)	4,550,732
Balance (in shares) at Dec. 31, 2020						345,000	213,751,145
Balance at Dec. 31, 2020	$ 0	$ 0	$ (988,900)	$ 126,125	$ (862,775)	$ 69	$ 42,750	8,033,313	(7,339,175)	736,957
Notes payable converted to common stock										$ 230,000
Exchange of stock options for common stock (in shares)										3,000,000
Net loss for the period										$ (5,898,467)
Net loss										(5,898,467)
Balance (in shares) at Sep. 30, 2021						345,000	252,285,754
Balance at Sep. 30, 2021						$ 69	$ 50,456	17,216,935	(13,111,517)	4,155,943
Balance (in shares) at Mar. 31, 2021						345,000	241,687,349
Balance at Mar. 31, 2021						$ 69	$ 48,337	12,153,798	(7,651,472)	4,550,732
Debt converted to common stock (in shares)						0	5,471,125
Notes payable converted to common stock						$ 0	$ 1,094	178,906	0	180,000
Common stock issued for liabilities (in shares)						0	3,327,280
Common stock issued for liabilities						$ 0	$ 665	322,645	0	323,310
Exchange of stock options for common stock (in shares)						0	900,000
Exchange of stock options for common stock						$ 0	$ 180	(180)	0	0
Options issued for compensation and services						0	0	2,340,723	0	2,340,723
Net loss for the period						0	0	0	(2,788,140)	(2,788,140)
Net loss						$ 0	$ 0	0	(2,788,140)	(2,788,140)
Balance (in shares) at Jun. 30, 2021						345,000	251,385,754
Balance at Jun. 30, 2021						$ 69	$ 50,276	14,995,892	(10,439,612)	4,606,625
Exchange of stock options for common stock (in shares)						0	900,000
Exchange of stock options for common stock						$ 0	$ 180	(180)	0	0
Options issued for compensation and services						0	0	2,221,223	0	2,221,223
Net loss for the period						0	0	0	(2,671,905)	(2,671,905)
Net loss						$ 0	$ 0	0	(2,671,905)	(2,671,905)
Balance (in shares) at Sep. 30, 2021						345,000	252,285,754
Balance at Sep. 30, 2021						$ 69	$ 50,456	$ 17,216,935	$ (13,111,517)	$ 4,155,943

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities
Net loss	$ (5,898,467)	$ (1,254,043)
Depreciation	0	126
Amortization - patents and other intangibles	60,772	60,172
Amortization - debt discount	73,720	296,738
Options issued for services	4,580,669	73,773
Prepaid expenses	52,363	(89,579)
Deposits	11,750	2,315
Accounts payable and accrued expenses	308,779	(124,161)
Net cash used in operating activities	(810,414)	(1,034,659)
Cash Flows from Investing Activities
Capitalized website costs	(12,007)	0
Cash Flows from Financing Activities
Payments on notes payable and long term debt	(90,505)	(46,986)
Proceeds from debt and warrants issued	334,651	1,047,151
Proceeds from private placement stock issued	4,913,200	0
Net cash provided by financing activities	5,157,346	1,000,165
Net change in cash	4,334,925	(34,494)
Cash, beginning of period	22,219	58,149
Cash, end of period	4,357,144	23,655
Supplemental Disclosure of Cash flow Information
Cash paid during the period for interest	92,434	50,271
Non-Cash Financing Activities
Notes payable converted to common stock	230,000	300,000
Stock options exchanged for common stock	600	360
Common stock issued to satisfy liabilities	393,574	0
Recognition of beneficial conversion feature	$ 0	$ 737,437

Note 1 - Business Organization,

Note 1 - Business Organization, Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 Business Organization, Nature of Business and Basis of Presentation Nature of Business The Coretec Group Inc. (the “Group”) (formerly 3DIcon “3DIcon” August 11, 1995, August 1, 2003 3DIcon 2001, 360 January 1, 2001, 3DIcon’s 3D Coretec Industries, LLC (“Coretec”), a wholly owned subsidiary of the Group (collectively the “Company”), was organized on September 2, 2015 not Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not 10 may not may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Summary of Significant Accounting Policies Principles of Consolidation The condensed consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not first not third Fair Value of Financial Instruments The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company: Current assets and current liabilities Notes payable and long term debt Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2021 2020 Options 53,711,609 20,212,174 Warrants 142,604,000 1,770,000 Series A convertible preferred stock 115,000 115,000 Convertible debt 40,914,134 35,755,783 Total potentially dilutive shares 237,344,743 57,852,957 Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not 5. Recent Accounting Pronouncements The following is a summary of accounting pronouncement recently adopted by the Company: In August 2020, 2020 06, Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 2020 06, no 2020 06 first 2024, first 2021 2020 06 2021 January 1, 2021. The following is a summary of recent accounting pronouncements not In May 2021, 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options January 1, 2022,

Note 3 - Notes Payable

Note 3 - Notes Payable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 3 Notes Payable September 30, December 31, 2021 2020 Notes payable: 3.8% $ - $ 46,580 Long term debt: 10% $ 1,346,075 $ 1,275,000 Less: Beneficial conversion feature $ - (862,775 ) Warrants issued $ (111,112 ) (106,167 ) Debt issue costs $ (33,929 ) (39,460 ) Total long term debt $ 1,201,034 $ 266,598 3.8% Insurance premium finance agreement, due June 2021 The Company entered into an insurance financing agreement in August 2020 ten June 2021. 10% January 2024, On October 4, 2019, five not The 10% Promissory Note, in a principal amount of $2,500,000, is due February 15, 2024 sixteen October 2019. may September 30, 2021, 2021. first Under the terms of the Promissory Note, DAF has the right to elect to convert all or part of the Promissory Notes at a price equal to seventy fifteen October 4, 2019, Under the terms of the DAF Credit Agreement, warrants to subscribe for and purchase 3,000,000 shares of common stock at an exercise price of $0.052 per share are available to be issued to DAF. The warrants will be issued in amounts of 150,000 and 210,000 per month as the advance is received during the funding period. In the event that funding advances deviate from the planned schedule then warrants will be issued pro-rata at 1.2 warrants for every $1 September 30, 2021, nine September 30, 2021 December 31, 2020, nine September 30, 2021 2020, Additionally, under the terms of the Credit Agreement, the Company agreed to pay a commitment fee of 3% of each advance and reimburse DAF for certain expenses in connection with the preparation, interpretation, performance and enforcement of the Credit Agreement. Those costs amounted to $10,350 and $42,000 for nine September 30, 2021 December 31, 2020 nine September 30, 2021 2020, On March 31, 2021, March 31, 2021. On April 29, 2021, April 29, 2021.

Note 4 - Commitments and Contin

Note 4 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 4 Commitments and Contingencies Warrants Warrants to subscribe for and purchase up to 3,000,000 shares of common stock at an exercise price of $0.052 per share were included under the terms of the DAF Credit Agreement. The warrants will be issued in amounts of 150,000 and 210,000 per month during the funding period. In the event that funding advances deviate from the planned schedule then warrants will be issued pro-rata at 1.2 warrants for every $1 September 30, 2021 not On March 2, 2021, one one March 5, 2021. may Warrants Summary The following table summarizes the Company’s warrant activity during the nine September 30, 2021: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2020 2,190,000 $ 0.0520 Granted - prefunded 51,500,000 0.0001 Granted 88,914,000 0.0812 Outstanding, September 30, 2021 142,604,000 $ 0.0515 4.30 $ 7,632,862 Options Stock options for employees, directors or consultants that vest immediately, are valued at the date of award, which does not The estimated fair value of options for common stock granted is determined using the Black-Scholes option pricing model. The Company does not On June 8, 2020, August 7, 2019. 1 144 144 not no nine September 30, 2021, On September 30, 2021, 2021, September 30, 2021 The following table summarizes the Company’s option activity during the nine September 30, 2021: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2020 20,212,174 $ 0.068 Expired (565 ) 420.000 Exchanged for common stock (5,000,000 ) 0.041 Granted 38,500,000 0.105 Outstanding, September 30, 2021 53,711,609 $ 0.093 4.42 $ 936,000 Exercisable, September 30, 2021 53,211,609 $ 0.093 4.43 $ 916,000 The Company had $56,173 in unrecognized compensation cost related to non-vested options, which is expected to be recognized over a weighted-average period of approximately 0.75 years. The following table summarizes the Company’s options as of September 30, 2021: Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 0.041 14,000,000 2.85 14,000,000 $ 0.065 1,000,000 3.75 500,000 $ 0.105 38,500,000 5.00 38,500,000 $ 0.240 208,160 5.47 208,160 $ 70.260 3,449 0.75 3,449 Total 53,711,609 4.42 53,211,609 Litigation, Claims, and Assessments The Company may not Office Leases On September 30, 2020, December 3, 2019. one January 1, 2020, 2021 nine September 30, 2021 2020, September 30, 2021, third Supply Agreement During September 2020, 500 Si6H12 March 31, 2021, 19 500 July 20, 2020, 150 September 30, 2021

Note 5 - Subsequent Events

Note 5 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 5 Subsequent Events On October 26, 2021, On October 27, 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not first not third
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company: Current assets and current liabilities Notes payable and long term debt
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2021 2020 Options 53,711,609 20,212,174 Warrants 142,604,000 1,770,000 Series A convertible preferred stock 115,000 115,000 Convertible debt 40,914,134 35,755,783 Total potentially dilutive shares 237,344,743 57,852,957
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not 5.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The following is a summary of accounting pronouncement recently adopted by the Company: In August 2020, 2020 06, Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 2020 06, no 2020 06 first 2024, first 2021 2020 06 2021 January 1, 2021. The following is a summary of recent accounting pronouncements not In May 2021, 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options January 1, 2022,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2021 2020 Options 53,711,609 20,212,174 Warrants 142,604,000 1,770,000 Series A convertible preferred stock 115,000 115,000 Convertible debt 40,914,134 35,755,783 Total potentially dilutive shares 237,344,743 57,852,957

Note 3 - Notes Payable (Tables)

Note 3 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	September 30, December 31, 2021 2020 Notes payable: 3.8% $ - $ 46,580 Long term debt: 10% $ 1,346,075 $ 1,275,000 Less: Beneficial conversion feature $ - (862,775 ) Warrants issued $ (111,112 ) (106,167 ) Debt issue costs $ (33,929 ) (39,460 ) Total long term debt $ 1,201,034 $ 266,598

Note 4 - Commitments and Cont_2

Note 4 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Warrant Activity [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2020 2,190,000 $ 0.0520 Granted - prefunded 51,500,000 0.0001 Granted 88,914,000 0.0812 Outstanding, September 30, 2021 142,604,000 $ 0.0515 4.30 $ 7,632,862
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2020 20,212,174 $ 0.068 Expired (565 ) 420.000 Exchanged for common stock (5,000,000 ) 0.041 Granted 38,500,000 0.105 Outstanding, September 30, 2021 53,711,609 $ 0.093 4.42 $ 936,000 Exercisable, September 30, 2021 53,211,609 $ 0.093 4.43 $ 916,000
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 0.041 14,000,000 2.85 14,000,000 $ 0.065 1,000,000 3.75 500,000 $ 0.105 38,500,000 5.00 38,500,000 $ 0.240 208,160 5.47 208,160 $ 70.260 3,449 0.75 3,449 Total 53,711,609 4.42 53,211,609

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Sep. 30, 2021	Jan. 01, 2021	Dec. 31, 2020
Additional Paid in Capital, Ending Balance	$ 17,216,935		$ 8,033,313
Retained Earnings (Accumulated Deficit), Ending Balance	$ (13,111,517)		$ (7,339,175)
Accounting Standards Update 2020-06 [Member]
Additional Paid in Capital, Ending Balance		$ (989,000)
Long-term Debt, Total		863,000
Retained Earnings (Accumulated Deficit), Ending Balance		$ 126,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Total potentially dilutive shares (in shares)	237,344,743	57,852,957
Options [Member]
Total potentially dilutive shares (in shares)	53,711,609	20,212,174
Warrant [Member]
Total potentially dilutive shares (in shares)	142,604,000	1,770,000
Series A Convertible Preferred Stock [Member]
Total potentially dilutive shares (in shares)	115,000	115,000
Convertible Debt Securities [Member]
Total potentially dilutive shares (in shares)	40,914,134	35,755,783

Note 3 - Notes Payable (Details

Note 3 - Notes Payable (Details Textual) - USD ($)	Apr. 29, 2021	Mar. 31, 2021	Oct. 04, 2019	Aug. 31, 2020	Mar. 31, 2021	Apr. 29, 2021	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 0.0515		$ 0.0520
Class of Warrant or Right, Issued Monthly (in shares)								88,914,000
Conversion of DAF Promissory Note into Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.0329	$ 0.0329			$ 0.0329	$ 0.0329
Debt Conversion, Original Debt, Amount	$ 180,000	$ 50,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)	5,471,125	1,519,757
Amortization of Debt Issuance Costs					$ 1,346	$ 3,772
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,000,000					2,604,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.052					$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares)								1.2
Allocated Cost of Warrants								$ 62,785		$ 135,706
Amortization Expense Associated With Warrants								$ 35,358	$ 19,398
Warrant Issued in Connection With Credit Agreement [Member] | Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares)			150,000					150,000
Warrant Issued in Connection With Credit Agreement [Member] | Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares)			210,000					210,000
DAF Credit Agreement Conversion Related Warrants [Member]
Interest Expense, Debt, Total					$ 5,513	$ 16,429
Three Point Eight Percent Insurance Premium Finance Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage				3.80%
Debt Instrument, Face Amount				$ 77,151
Debt Instrument, Term (Month)				10 months
Debt Instrument, Periodic Payment, Total				$ 7,849
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage			10.00%					10.00%		10.00%
Debt Agreement, Maximum Borrowing Capacity			$ 2,500,000
Debt Instrument, Number of Tranches			16
Proceeds from Notes Payable, Total								$ 2,170,000
Debt Instrument, Period of Monthly Advance Interest Payments (Month)			12 months
Debt Instrument, Period Following Advance Interest Payments (Month)			36 months
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			70.00%
Debt Instrument, Convertible, Threshold Trading Days			15
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 0.0329
Line of Credit Facility, Commitment Fee Percentage			3.00%
Line of Credit Facility, Commitment Fee and Debt-related Expenses to Be Amortized								10,350		$ 42,000
Amortization Associated With Commitment Fee								$ 11,978	$ 6,080
Credit Agreement And Note [Member] | Forecast [Member]
Proceeds from Notes Payable, Total							$ 330,000
Credit Agreement And Note [Member] | Minimum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche			$ 125,000
Credit Agreement And Note [Member] | Maximum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche			$ 175,000

Note 3 - Notes Payable - Schedu

Note 3 - Notes Payable - Schedule of Debt (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Notes payable	$ 0	$ 46,580
Total long term debt	1,201,034	266,598
The 3.8% Insurance Premium Finance Agreement [Member]
Notes payable	0	46,580
Credit Agreement And Note [Member]
10% Promissory note due January 2024	1,346,075	1,275,000
Beneficial conversion feature	0	(862,775)
Warrants issued	(111,112)	(106,167)
Debt issue costs	$ (33,929)	$ (39,460)

Note 3 - Notes Payable - Sche_2

Note 3 - Notes Payable - Schedule of Debt (Details) (Parentheticals)	Sep. 30, 2021	Dec. 31, 2020	Oct. 04, 2019
The 3.8% Insurance Premium Finance Agreement [Member]
Interest rate	3.80%	3.80%
Credit Agreement And Note [Member]
Interest rate	10.00%	10.00%	10.00%

Note 4 - Commitments and Cont_3

Note 4 - Commitments and Contingencies (Details Textual)	Sep. 30, 2021USD ($)$ / sharesshares	Mar. 02, 2021USD ($)$ / sharesshares	Jul. 20, 2020USD ($)	Jun. 08, 2020shares	Jan. 01, 2020USD ($)	Oct. 04, 2019$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Dec. 31, 2020$ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.0515						$ 0.0515		$ 0.0520
Class of Warrant or Right, Issued Monthly (in shares)							88,914,000
Share Exchange Agreement, Number of Options Authorized (in shares)				21,500,000
Share Exchange Agreement, Exchange Ratio				0.6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exchanged (in shares)							5,000,000
Stock Issued During Period, Shares, Stock Options Exchanged for Common Shares (in shares)							3,000,000
Stock Cancelled and Reissued During Period (in shares)							23,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.105
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $	$ 56,173						$ 56,173
Operating Lease, Expense | $							11,340	$ 22,134
Operating Lease, Payments | $	800
Evonik Operations GmbH [Member]
Purchase Obligation, Total | $	92,500						$ 92,500	$ 185,000
Payments for Research and Development, Supply Agreement | $			$ 92,500
Ann Arbor, Michigan [Member]
Lessee, Operating Lease, Liability, to be Paid, Total | $					$ 15,120
Operating Leases, Rent Expense, Monthly | $					$ 1,260
Ann Arbor, Michigan [Member] | Other Income [Member]
Operating Lease, Other Income | $	$ 45,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exchanged (in shares)							5,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares							$ 0.105
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							9 months
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		23,500,000
Proceeds from Issuance or Sale of Equity, Total | $		$ 6,000,000
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,604,000					3,000,000	2,604,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.052					$ 0.052	$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares)							1.2
Class of Warrant or Right, Issued During Period (in shares)							2,604,000
Warrant Issued in Connection With Credit Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0						0
Warrant Issued in Connection With Credit Agreement [Member] | Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares)						150,000	150,000
Warrant Issued in Connection With Credit Agreement [Member] | Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares)						210,000	210,000
Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		51,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.0001
Class of Warrant or Right, Issued Monthly (in shares)							51,500,000
Class of Warrant or Right, Purchase Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.08
Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		82,500,000
Class of Warrant or Right, Purchase Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.0799
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.10
Warrants Ownership Percentage, Maximum Limit		8.00%

Note 4 - Commitments and Cont_4

Note 4 - Commitments and Contingencies - Warrants (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Outstanding, number of warrants (in shares) | shares	2,190,000
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.0520
Granted, number of warrants (in shares) | shares	88,914,000
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.0812
Outstanding, number of warrants (in shares) | shares	142,604,000
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.0515
Outstanding, weighted-average remaining life (Year)	4 years 3 months 18 days
Outstanding, aggregate intrinsic value | $	$ 7,632,862
Pre-funded Warrant [Member]
Granted, number of warrants (in shares) | shares	51,500,000
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.0001

Note 4 - Commitments and Cont_5

Note 4 - Commitments and Contingencies - Option Activity (Details)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares
Exchanged for common stock (in shares) | shares		(5,000,000)
Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.105
Share-based Payment Arrangement, Option [Member]
Outstanding (in shares) | shares		20,212,174
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares		$ 0.068
Expired (in shares) | shares		(565)
Expired, Weighted Average Exercise Price (in dollars per share) | $ / shares		$ 420
Exchanged for common stock (in shares) | shares		(5,000,000)
Exchanged for common stock, Weighted Average Exercise Price (in dollars per share) | $ / shares		$ 0.041
Granted (in shares) | shares		38,500,000
Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares		$ 0.105
Outstanding (in shares) | shares	53,711,609	53,711,609
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.093	$ 0.093
Outstanding, Weighted Average Remaining Life in Years (Year)		4 years 5 months 1 day
Outstanding, Aggregate intrinsic value | $	$ 936,000	$ 936,000
Exercisable (in shares) | shares	53,211,609	53,211,609
Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.093	$ 0.093
Exercisable, Weighted Average Remaining Life (Year)		4 years 5 months 4 days
Exercisable, Aggregate intrinsic value | $	$ 916,000	$ 916,000

Note 4 - Commitments and Cont_6

Note 4 - Commitments and Contingencies - Shares Authorized Under Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Option Outstanding, Number Of Options (in shares)	53,711,609
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 5 months 1 day
Option Exercisable, Number Of Options (in shares)	53,211,609
Exercise Price Range One [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.041
Option Outstanding, Number Of Options (in shares)	14,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	2 years 10 months 6 days
Option Exercisable, Number Of Options (in shares)	14,000,000
Exercise Price Range Two [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.065
Option Outstanding, Number Of Options (in shares)	1,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 9 months
Option Exercisable, Number Of Options (in shares)	500,000
Exercise Price Range Three [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.105
Option Outstanding, Number Of Options (in shares)	38,500,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	5 years
Option Exercisable, Number Of Options (in shares)	38,500,000
Exercise Price Range Four [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.240
Option Outstanding, Number Of Options (in shares)	208,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	5 years 5 months 19 days
Option Exercisable, Number Of Options (in shares)	208,160
Exercise Price Range Five [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 70.260
Option Outstanding, Number Of Options (in shares)	3,449
Option Exercisable, Weighted Average Remaining Life In Years (Year)	9 months
Option Exercisable, Number Of Options (in shares)	3,449

Note 5 - Subsequent Events (Det

Note 5 - Subsequent Events (Details Textual) - Conversion of DAF Promissory Note into Common Stock [Member] - USD ($)	Oct. 27, 2021	Apr. 29, 2021	Mar. 31, 2021
Debt Conversion, Original Debt, Amount		$ 180,000	$ 50,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.0329	$ 0.0329
Debt Conversion, Converted Instrument, Shares Issued (in shares)		5,471,125	1,519,757
Subsequent Event [Member]
Debt Conversion, Original Debt, Amount	$ 35,458
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.0329
Debt Conversion, Converted Instrument, Shares Issued (in shares)	1,077,746